Raloxifene reduces triple-negative breast cancer tumor growth and decreases EGFR expression

Taurin,Sebastien; Allen,Kirstie   M.; Scandlyn,Marissa  J.; Rosengren,Rhonda   J.

doi:10.3892/ijo.2013.2012

Raloxifene reduces triple-negative breast cancer tumor growth and decreases EGFR expression

Authors:
- Sebastien Taurin
- Kirstie M. Allen
- Marissa J. Scandlyn
- Rhonda J. Rosengren
View Affiliations

Affiliations: Department of Pharmacology and Toxicology, University of Otago, Adams Building, Dunedin 9016, New Zealand
Published online on: July 10, 2013 https://doi.org/10.3892/ijo.2013.2012
Pages: 785-792

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The poor prognosis of patients with triple-negative breast cancer (TNBC) and the lack of targeted treatments have raised the need for alternative therapies. Previous studies have suggested an effect of raloxifene, a selective estrogen receptor modulator that is independent of the estrogen receptor (ER). Therefore, we assessed the therapeutic value of raloxifene in TNBC mouse models. Mice received a daily oral treatment with different doses of raloxifene. Tumor progression was monitored weekly; in addition microvessel density, proliferation, migration and invasion, apoptosis and tumorigenicity were analyzed. This study demonstrates that raloxifene (0.85 mg/kg) prevents TNBC tumor growth and induces tumor regression. The treated tumors showed a 54% decreased microvascular density and proliferation and a 7-fold increase in apoptosis. The underlying therapeutic mechanism of raloxifene was associated with a 27-fold decrease in the expression of the epidermal growth factor receptor (EGFR). Moreover, raloxifene promoted the translocation of EGFR into endosomes associated with decreased cell migration, cell invasion and tumorigenicity in vitro. Together, these data showed that raloxifene acts independently of the ER and may be relevant for the treatment as well as control the progression of TNBC.

View Figures

View References

1	Sporn MB, Dowsett SA, Mershon J and Bryant HU: Role of raloxifene in breast cancer prevention in postmenopausal women: clinical evidence and potential mechanisms of action. Clin Ther. 26:830–840. 2004. View Article : Google Scholar : PubMed/NCBI
2	Jordan VC and Koerner S: Inhibition of oestradiol binding to mouse uterine and vaginal oestrogen receptors by triphenylethylenes. J Endocrinol. 64:193–194. 1975. View Article : Google Scholar : PubMed/NCBI
3	Croxtall JD, Emmas C, White JO, Choudhary Q and Flower RJ: Tamoxifen inhibits growth of oestrogen receptor-negative A549 cells. Biochem Pharmacol. 47:197–202. 1994. View Article : Google Scholar : PubMed/NCBI
4	Couldwell WT, Weiss MH, DeGiorgio CM, et al: Clinical and radiographic response in a minority of patients with recurrent malignant gliomas treated with high-dose tamoxifen. Neurosurgery. 32:485–490. 1993. View Article : Google Scholar : PubMed/NCBI
5	Del Prete SA, Maurer LH, O’Donnell J, Forcier RJ and LeMarbre P: Combination chemotherapy with cisplatin, carmustine, dacarbazine and tamoxifen in metastatic melanoma. Cancer Treat Rep. 68:1403–1405. 1984.PubMed/NCBI
6	Murphy LC and Sutherland RL: Differential effects of tamoxifen and analogs with nonbasic side chains on cell proliferation in vitro. Endocrinology. 116:1071–1078. 1985. View Article : Google Scholar : PubMed/NCBI
7	Plowman PN: Tamoxifen as adjuvant therapy in breast cancer. Current status Drugs. 46:819–833. 1993.PubMed/NCBI
8	Mandlekar S and Kong ANT: Mechanisms of tamoxifen-induced apoptosis. Apoptosis. 6:469–477. 2001. View Article : Google Scholar
9	Carey LA, Dees EC, Sawyer L, et al: The triple-negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 13:2329–2334. 2007. View Article : Google Scholar : PubMed/NCBI
10	Kaplan HG and Malmgren JA: Impact of triple-negative phenotype on breast cancer prognosis. Breast J. 14:456–463. 2008. View Article : Google Scholar : PubMed/NCBI
11	Somers-Edgar TJ, Taurin S, Larsen L, Chandramouli A, Nelson MA and Rosengren RJ: Mechanisms for the activity of heterocyclic cyclohexanone curcumin derivatives in estrogen receptor negative human breast cancer cell lines. Invest New Drugs. 29:87–97. 2011. View Article : Google Scholar
12	Taurin S, Sandbo N, Qin Y, Browning D and Dulin NO: Phosphorylation of β-catenin by cyclic AMP-dependent protein kinase. J Biol Chem. 281:9971–9976. 2006.
13	Reagan-Shaw S, Nihal M and Ahmad N: Dose translation from animal to human studies revisited. FASEB J. 22:659–661. 2008. View Article : Google Scholar : PubMed/NCBI
14	Nielsen TO, Hsu FD, Jensen K, et al: Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 10:5367–5374. 2004. View Article : Google Scholar : PubMed/NCBI
15	Rush JS, Quinalty LM, Engelman L, Sherry DM and Ceresa BP: Endosomal accumulation of the activated epidermal growth factor receptor (EGFR) induces apoptosis. J Biol Chem. 287:712–722. 2012. View Article : Google Scholar : PubMed/NCBI
16	Ueno NT and Zhang D: Targeting EGFR in triple-negative breast cancer. J Cancer. 2:324–328. 2011. View Article : Google Scholar : PubMed/NCBI
17	Nickerson NK, Mohammad KS, Gilmore JL, et al: Decreased autocrine EGFR signaling in metastatic breast cancer cells inhibits tumor growth in bone and mammary fat pad. PLoS One. 7:e302552012. View Article : Google Scholar : PubMed/NCBI
18	Zoncu R, Perera RM, Balkin DM, Pirruccello M, Toomre D and De Camilli P: A phosphoinositide switch controls the maturation and signaling properties of APPL endosomes. Cell. 136:1110–1121. 2009. View Article : Google Scholar : PubMed/NCBI
19	Pol A, Lu A, Pons M, Peiró S and Enrich C: Epidermal growth factor-mediated caveolin recruitment to early endosomes and MAPK activation. J Biol Chem. 275:30566–30572. 2000. View Article : Google Scholar : PubMed/NCBI
20	Freedman VH and Shin SI: Cellular tumorigenicity in nude mice: correlation with cell growth in semi-solid medium. Cell. 3:355–359. 1974. View Article : Google Scholar : PubMed/NCBI
21	Riggs BL and Hartmann LC: Selective estrogen-receptor modulators - mechanisms of action and application to clinical practice. N Engl J Med. 348:618–629. 2003. View Article : Google Scholar : PubMed/NCBI
22	Perry RR, Kang Y and Greaves B: Effects of tamoxifen on growth and apoptosis of estrogen-dependent and -independent human breast cancer cells. Ann Surg Oncol. 2:238–245. 1995. View Article : Google Scholar : PubMed/NCBI
23	Gelmann EP: Tamoxifen induction of apoptosis in estrogen receptor-negative cancers: new tricks for an old dog? J Natl Cancer Inst. 88:224–226. 1996. View Article : Google Scholar : PubMed/NCBI
24	Kim HT, Kim BC, Kim IY, et al: Raloxifene, a mixed estrogen agonist/antagonist, induces apoptosis through cleavage of BAD in TSU-PR1 human cancer cells. J Biol Chem. 277:32510–32515. 2002. View Article : Google Scholar : PubMed/NCBI
25	Eisen SF and Brown HA: Selective estrogen receptor (ER) modulators differentially regulate phospholipase D catalytic activity in ER-negative breast cancer cells. Mol Pharmacol. 62:911–920. 2002. View Article : Google Scholar
26	Todorova VK, Kaufmann Y, Luo S and Klimberg VS: Tamoxifen and raloxifene suppress the proliferation of estrogen receptor-negative cells through inhibition of glutamine uptake. Cancer Chemother Pharmacol. 67:285–291. 2011. View Article : Google Scholar : PubMed/NCBI
27	Bosch A, Eroles P, Zaragoza R, Vina JR and Lluch A: Triple-negative breast cancer: molecular features, pathogenesis, treatment and current lines of research. Cancer Treat Rev. 36:206–215. 2010. View Article : Google Scholar : PubMed/NCBI
28	Cho EY, Chang MH, Choi YL, et al: Potential candidate biomarkers for heterogeneity in triple-negative breast cancer (TNBC). Cancer Chemother Pharmacol. 68:753–761. 2011. View Article : Google Scholar : PubMed/NCBI
29	Hyatt DC and Ceresa BP: Cellular localization of the activated EGFR determines its effect on cell growth in MDA-MB-468 cells. Exp Cell Res. 314:3415–3425. 2008. View Article : Google Scholar : PubMed/NCBI
30	de Medina P, Payre B, Boubekeur N, et al: Ligands of the antiestrogen-binding site induce active cell death and autophagy in human breast cancer cells through the modulation of cholesterol metabolism. Cell Death Differ. 16:1372–1384. 2009.PubMed/NCBI
31	de Medina P, Paillasse MR, Segala G, Poirot M and Silvente-Poirot S: Identification and pharmacological characterization of cholesterol-5,6-epoxide hydrolase as a target for tamoxifen and AEBS ligands. Proc Natl Acad Sci USA. 107:13520–13525. 2010.PubMed/NCBI
32	Payre B, de Medina P, Boubekeur N, et al: Microsomal antiestrogen-binding site ligands induce growth control and differentiation of human breast cancer cells through the modulation of cholesterol metabolism. Mol Cancer Ther. 7:3707–3718. 2008. View Article : Google Scholar
33	Simonsen A and Tooze SA: Coordination of membrane events during autophagy by multiple class III PI3-kinase complexes. J Cell Biol. 186:773–782. 2009. View Article : Google Scholar : PubMed/NCBI
34	Razi M, Chan EY and Tooze SA: Early endosomes and endosomal coatomer are required for autophagy. J Cell Biol. 185:305–321. 2009. View Article : Google Scholar : PubMed/NCBI
35	Sigismund S, Woelk T, Puri C, et al: Clathrin-independent endocytosis of ubiquitinated cargos. Proc Natl Acad Sci USA. 102:2760–2765. 2005. View Article : Google Scholar : PubMed/NCBI
36	Aguilar RC and Wendland B: Endocytosis of membrane receptors: two pathways are better than one. Proc Natl Acad Sci USA. 102:2679–2680. 2005. View Article : Google Scholar : PubMed/NCBI
37	Couet J, Sargiacomo M and Lisanti MP: Interaction of a receptor tyrosine kinase, EGF-R, with caveolins. Caveolin binding negatively regulates tyrosine and serine/threonine kinase activities. J Biol Chem. 272:30429–30438. 1997. View Article : Google Scholar
38	Litwiniuk MM, Roznowski K, Filas V, et al: Expression of estrogen receptor beta in the breast carcinoma of BRCA1 mutation carriers. BMC Cancer. 8:1002008. View Article : Google Scholar : PubMed/NCBI
39	Vladusic EA, Hornby AE, Guerra-Vladusic FK, Lakins J and Lupu R: Expression and regulation of estrogen receptor beta in human breast tumors and cell lines. Oncol Rep. 7:157–167. 2000.PubMed/NCBI
40	Kuiper GGJM, Lemmen JG, Carlsson B, et al: Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor β. Endocrinology. 139:4252–4263. 1998.
41	Pinton G, Thomas W, Bellini P, et al: Estrogen receptor β exerts tumor repressive functions in human malignant pleural mesothelioma via EGFR inactivation and affects response to gefitinib. PLoS One. 5:e141102010.
42	Lee W-L, Chao H-T, Cheng M-H and Wang P-H: Rationale for using raloxifene to prevent both osteoporosis and breast cancer in postmenopausal women. Maturitas. 60:92–107. 2008. View Article : Google Scholar : PubMed/NCBI
43	Wang Z, Zhang X, Shen P, Loggie BW, Chang Y and Deuel TF: A variant of estrogen receptor-α, hER-α36: transduction of estrogen- and antiestrogen-dependent membrane-initiated mitogenic signaling. Proc Natl Acad Sci USA. 103:9063–9068. 2006.
44	Zhang XT, Kang LG, Ding L, Vranic S, Gatalica Z and Wang ZY: A positive feedback loop of ER-alpha36/EGFR promotes malignant growth of ER-negative breast cancer cells. Oncogene. 30:770–780. 2011. View Article : Google Scholar : PubMed/NCBI
45	Lin SL, Yan LY, Zhang XT, et al: ER-alpha36, a variant of ER-alpha, promotes tamoxifen agonist action in endometrial cancer cells via the MAPK/ERK and PI3K/Akt pathways. PLoS One. 5:e90132010. View Article : Google Scholar
46	Nguyen DX, Bos PD and Massague J: Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer. 9:274–284. 2009. View Article : Google Scholar : PubMed/NCBI
47	Viale G, Rotmensz N, Maisonneuve P, et al: Invasive ductal carcinoma of the breast with the ‘triple-negative’ phenotype: prognostic implications of EGFR immunoreactivity. Breast Cancer Res Treat. 116:317–328. 2009.